These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 9422816

  • 1. Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats.
    Gardiner SM, Kemp PA, Brunner-Ferber F, Bennett T.
    Br J Pharmacol; 1997 Dec; 122(8):1694-701. PubMed ID: 9422816
    [Abstract] [Full Text] [Related]

  • 2. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
    Gardiner SM, Kemp PA, Brunner-Ferber F, Bennett T.
    Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
    [Abstract] [Full Text] [Related]

  • 3. Enhanced involvement of endothelin in the haemodynamic sequelae of endotoxaemia in conscious, hypertensive, transgenic ((mRen-2)27) rats.
    Gardiner SM, Kemp PA, March JE, Bennett T.
    Br J Pharmacol; 1998 Apr; 123(7):1403-8. PubMed ID: 9579736
    [Abstract] [Full Text] [Related]

  • 4. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
    Seccia TM, Belloni AS, Guidolin D, Sticchi D, Nussdorfer GG, Pessina AC, Rossi GP.
    J Hypertens; 2006 Jul; 24(7):1419-27. PubMed ID: 16794493
    [Abstract] [Full Text] [Related]

  • 5. The influence of antibodies to TNF-alpha and IL-1beta on haemodynamic responses to the cytokines, and to lipopolysaccharide, in conscious rats.
    Gardiner SM, Kemp PA, March JE, Woolley J, Bennett T.
    Br J Pharmacol; 1998 Dec; 125(7):1543-50. PubMed ID: 9884083
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure.
    Barbe F, Su JB, Guyene TT, Crozatier B, Ménard J, Hittinger L.
    Am J Physiol; 1996 Jun; 270(6 Pt 2):H1985-92. PubMed ID: 8764248
    [Abstract] [Full Text] [Related]

  • 11. The contribution of nitric oxide to cardiovascular status and responses to vasodilators in conscious, hypertensive, transgenic ((mRen-2)27) rats.
    Gardiner SM, March JE, Kemp PA, Bennett T.
    Br J Pharmacol; 1998 May; 124(2):299-306. PubMed ID: 9641546
    [Abstract] [Full Text] [Related]

  • 12. Effects of angiotensin-converting enzyme inhibition on arterial, venous and capillary functions in cat skeletal muscle in vivo.
    Ekelund U.
    Acta Physiol Scand; 1996 Sep; 158(1):29-37. PubMed ID: 8876745
    [Abstract] [Full Text] [Related]

  • 13. Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats.
    Chen C, Lokhandwala MF.
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Aug; 352(2):194-200. PubMed ID: 7477443
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
    Zhang X, Recchia FA, Bernstein R, Xu X, Nasjletti A, Hintze TH.
    J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
    [Abstract] [Full Text] [Related]

  • 17. Acute hemodynamic effects of the active metabolite of imidapril, (4S)-3-((2S)-2-[N-((1S)-1-carboxy-3-phenyl-propyl)amino]propionyl)-1- methyl-2-oxoimidazolidine-4-carboxylic acid, and enalaprilat in anesthetized dogs.
    Ikeo T, Yabana H, Kurosawa H, Kaburaki M, Kikkawa K, Narita H, Murata S, Yamaguchi I.
    Arzneimittelforschung; 1992 Sep; 42(9):1109-14. PubMed ID: 1332727
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological studies of N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new long-acting antihypertensive vasodilator.
    Baldoli E, Bianchi G, Corsico N, Di Francesco GF.
    Arzneimittelforschung; 1985 Sep; 35(5):818-26. PubMed ID: 2862874
    [Abstract] [Full Text] [Related]

  • 19. Regional hemodynamic effects of neutral endopeptidase inhibition and angiotensin (AT(1)) receptor antagonism alone or in combination in conscious spontaneously hypertensive rats.
    Gardiner SM, March JE, Kemp PA, Ballard SA, Bennett T.
    J Pharmacol Exp Ther; 2006 Oct; 319(1):340-8. PubMed ID: 16825530
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.